- Pharmacological
- Nonpharmacological
- Others
Chronic Bronchitis Market was valued at USD 5.8 billion in 2023 and is poised to grow at a CAGR of 5.4% over 2024-2030. Chronic Bronchitis is defined as a productive cough, one that produces sputum, which lasts for three months or more per year for at least two years, and the most common cause is tobacco smoking, including other factors such as air pollution and genetics. According to the Centers for Disease Control and Prevention, 9.3 million people were diagnosed with chronic bronchitis in the USA, in 2018. The increasing prevalence of COPD and growing chronic bronchitis market demand for combination therapy will act as the chronic bronchitis market growth drivers. However, the high cost of treatment and the lack of awareness of the disease might cause hindrance in the growth of the market. The rising prevalence of smoking and advancements in clinical research and innovations are opportunities for the expansion of the market.
Chronic Bronchitis Market Key Developments:
- In Feb 2022, AstraZeneca and Glenmark Pharmaceuticals Ltd. entered into an exclusive licensing agreement for Budesonide inhalation suspension in Colombia.
- In Feb 2022, Sunovion’s Brovana was approved by the US FDA for treating bronchoconstriction in chronic obstructive pulmonary disease patients.
Chronic Bronchitis Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
5.4%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Chronic Bronchitis Market Dynamics
An increasing number of smokers, and the rising prevalence of lung disorders such as bronchitis, asthma, and COPD, are the major factors driving the growth of the chronic bronchitis market. Moreover, government-led initiatives to raise awareness of the treatment of lung disorders, have resulted in progress for combination medicines and small cell therapy. Thus, the increased awareness, research, and development for chronic diseases will lead to the growth of the market within the forecast period.
North-America Got Significant Share
Chronic Bronchitis Market Regional Analysis
Chronic Bronchitis market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to the World Health Organization, COPD is the third leading cause of death worldwide, which caused 3.23 million deaths in 2019. As per the Centers for Disease Control and Prevention, in the USA, over 32.51 million people used cigarettes in 2020, and in Canada, the prevalence was 12%, with around 3.7 million consumers. As per the COPD Foundation, smoking is responsible for 90% of all COPD fatalities, resulting in approximately 4,80,000 deaths every year in the USA. The North America Chronic Bronchitis market is expected to dominate the lysosomal storage disorders market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players, and the rising prevalence and incidence of respiratory diseases in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The chronic bronchitis market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Chronic Bronchitis Market Segmentation
By Treatment
By Drug Class
- Bronchodilators
- Glucocorticoids
- Antibiotics
- Phosphodiesterase-4 Inhibitors
- Others
By Route of Administration
- Oral
- Parenteral
- Inhalational
- Others
By End User
- Hospitals
- Specialty Clinics
- Others
Frequently Asked Questions
The Chronic Bronchitis market was valued at USD 5.8 million in 2022 and is expected to grow at a 5.4% CAGR over the forecast period 2023 – 2029.
The rising prevalence of smoking and advancements in clinical research and innovations are the key opportunities for the Chronic Bronchitis market.
The increasing prevalence of COPD and growing demand for combination therapy are the growth drivers in the Chronic Bronchitis market.
Bayer AG, Boehringer Ingelheim International, AstraZeneca, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Amneal Pharmaceuticals LLC., Aurobindo Pharma, Johnsons & Johnsons Private, limited, and GlaxoSmithKline Plc. are a few companies operating in the Chronic Bronchitis market.
| 1.Executive Summary |
| 2.Global Chronic Bronchitis Market Introduction |
| 2.1.Global Chronic Bronchitis Market - Taxonomy |
| 2.2.Global Chronic Bronchitis Market - Definitions |
| 2.2.1.Treatment |
| 2.2.2. Drug Class |
| 2.2.3.Route of Administration |
| 2.2.4.End User |
| 2.2.5.Region |
| 3.Global Chronic Bronchitis Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Chronic Bronchitis Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Chronic Bronchitis Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Pharmacological |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Nonpharmacological |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Chronic Bronchitis Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Bronchodilators |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Glucocorticoids |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Antibiotics |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Phosphodiesterase-4 Inhibitors |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Chronic Bronchitis Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Parenteral |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Inhalational |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Chronic Bronchitis Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Specialty Clinics |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Others |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Chronic Bronchitis Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Chronic Bronchitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Pharmacological |
| 10.1.2.Nonpharmacological |
| 10.1.3.Others |
| 10.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Bronchodilators |
| 10.2.2.Glucocorticoids |
| 10.2.3.Antibiotics |
| 10.2.4.Phosphodiesterase-4 Inhibitors |
| 10.2.5.Others |
| 10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oral |
| 10.3.2.Parenteral |
| 10.3.3.Inhalational |
| 10.3.4.Others |
| 10.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospitals |
| 10.4.2.Specialty Clinics |
| 10.4.3.Others |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Chronic Bronchitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Pharmacological |
| 11.1.2.Nonpharmacological |
| 11.1.3.Others |
| 11.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Bronchodilators |
| 11.2.2.Glucocorticoids |
| 11.2.3.Antibiotics |
| 11.2.4.Phosphodiesterase-4 Inhibitors |
| 11.2.5.Others |
| 11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oral |
| 11.3.2.Parenteral |
| 11.3.3.Inhalational |
| 11.3.4.Others |
| 11.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospitals |
| 11.4.2.Specialty Clinics |
| 11.4.3.Others |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Chronic Bronchitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Pharmacological |
| 12.1.2.Nonpharmacological |
| 12.1.3.Others |
| 12.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Bronchodilators |
| 12.2.2.Glucocorticoids |
| 12.2.3.Antibiotics |
| 12.2.4.Phosphodiesterase-4 Inhibitors |
| 12.2.5.Others |
| 12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oral |
| 12.3.2.Parenteral |
| 12.3.3.Inhalational |
| 12.3.4.Others |
| 12.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospitals |
| 12.4.2.Specialty Clinics |
| 12.4.3.Others |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Chronic Bronchitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Pharmacological |
| 13.1.2.Nonpharmacological |
| 13.1.3.Others |
| 13.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Bronchodilators |
| 13.2.2.Glucocorticoids |
| 13.2.3.Antibiotics |
| 13.2.4.Phosphodiesterase-4 Inhibitors |
| 13.2.5.Others |
| 13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oral |
| 13.3.2.Parenteral |
| 13.3.3.Inhalational |
| 13.3.4.Others |
| 13.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospitals |
| 13.4.2.Specialty Clinics |
| 13.4.3.Others |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Chronic Bronchitis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Pharmacological |
| 14.1.2.Nonpharmacological |
| 14.1.3.Others |
| 14.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Bronchodilators |
| 14.2.2.Glucocorticoids |
| 14.2.3.Antibiotics |
| 14.2.4.Phosphodiesterase-4 Inhibitors |
| 14.2.5.Others |
| 14.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oral |
| 14.3.2.Parenteral |
| 14.3.3.Inhalational |
| 14.3.4.Others |
| 14.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospitals |
| 14.4.2.Specialty Clinics |
| 14.4.3.Others |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Bayer AG |
| 15.2.2.Boehringer Ingelheim International |
| 15.2.3.AstraZeneca |
| 15.2.4.Teva Pharmaceutical Industries Ltd. |
| 15.2.5.Sun Pharmaceutical Industries Ltd. |
| 15.2.6.Hikma Pharmaceutical PLC |
| 15.2.7.Amneal Pharmaceuticals LLC. |
| 15.2.8.Aurobindo Pharma |
| 15.2.9.Johnsons & Johnsons Private limited |
| 15.2.10.GlaxoSmithKline Plc. |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Bayer AG
- Boehringer Ingelheim International
- AstraZeneca
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceutical PLC
- Amneal Pharmaceuticals LLC.
- Aurobindo Pharma
- Johnsons & Johnsons Private limited
- GlaxoSmithKline Plc.